All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

dulaglutide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
glucagon-like peptide (GLP) analogues and agonists	4885	923950-08-7

Description:

Molecule	Description
Synonyms: dulaglutide trulicity LY2189265	a glucagon-like peptide-1 receptor agonist; GLP-1 immunoglobulin G (IgG4) Fc fusion protein with extended activity Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
0.16	mg	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Nov. 22, 2014	EMA
Sept. 18, 2014	FDA	ELI LILLY AND CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood glucose increased	645.51	16.13	335	17893	94911	90515308
Nausea	504.13	16.13	838	17390	1109478	89500741
Injection site pain	494.23	16.13	350	17878	173349	90436870
Glycosylated haemoglobin increased	481.17	16.13	162	18066	15400	90594819
Accidental underdose	439.91	16.13	88	18140	1003	90609216
Extra dose administered	278.13	16.13	94	18134	9024	90601195
Incorrect dose administered	261.58	16.13	175	18053	78755	90531464
Diabetic ketoacidosis	249.78	16.13	114	18114	24293	90585926
Vomiting	181.41	16.13	451	17777	787842	89822377
Inappropriate schedule of product administration	165.22	16.13	176	18052	149757	90460462
Product dose omission issue	161.95	16.13	243	17985	291444	90318775
Injection site pruritus	156.12	16.13	110	18118	53724	90556495
Injection site haemorrhage	156.06	16.13	87	18141	28231	90581988
Pancreatitis	153.94	16.13	121	18107	69705	90540514
Injection site erythema	148.11	16.13	137	18091	98365	90511854
Accidental overdose	145.35	16.13	83	18145	28190	90582029
Euglycaemic diabetic ketoacidosis	139.57	16.13	51	18177	6150	90604069
Lactic acidosis	139.15	16.13	100	18128	50363	90559856
Product administered at inappropriate site	131.33	16.13	44	18184	4107	90606112
Injury associated with device	124.31	16.13	43	18185	4421	90605798
Acute kidney injury	118.98	16.13	223	18005	320164	90290055
Diabetic metabolic decompensation	113.58	16.13	33	18195	1924	90608295
Hypoglycaemia	112.49	16.13	101	18127	69747	90540472
Blood glucose abnormal	92.88	16.13	43	18185	9449	90600770
Injection site mass	90.42	16.13	56	18172	22034	90588185
Injection site bruising	84.92	16.13	76	18152	52231	90557988
Blood glucose decreased	82.48	16.13	54	18174	23375	90586844
Diarrhoea	77.66	16.13	383	17845	938807	89671412
Injection site rash	71.45	16.13	50	18178	24123	90586096
Abdominal pain upper	68.40	16.13	183	18045	332491	90277728
Injection site urticaria	62.14	16.13	41	18187	17970	90592249
Pancreatic carcinoma	60.99	16.13	31	18197	8346	90601873
Pancreatitis acute	60.90	16.13	51	18177	32064	90578155
Eructation	58.75	16.13	33	18195	10849	90599370
Diabetes mellitus inadequate control	58.40	16.13	40	18188	18644	90591575
Systemic lupus erythematosus	57.31	16.13	4	18224	361892	90248327
Ketoacidosis	56.78	16.13	26	18202	5569	90604650
Infusion related reaction	54.90	16.13	9	18219	416771	90193448
Arthropathy	48.02	16.13	8	18220	366234	90243985
Transcription medication error	47.60	16.13	11	18217	256	90609963
Wrong technique in product usage process	47.45	16.13	65	18163	71506	90538713
Contraindicated product administered	46.71	16.13	5	18223	320134	90290085
Impaired gastric emptying	46.24	16.13	30	18198	12779	90597440
Dehydration	46.16	16.13	113	18115	194334	90415885
Wound	46.13	16.13	4	18224	302976	90307243
Stomatitis	43.59	16.13	3	18225	274695	90335524
Injection site swelling	42.19	16.13	56	18172	59783	90550436
Treatment failure	41.29	16.13	6	18222	303922	90306297
Blood glucose fluctuation	40.51	16.13	20	18208	5063	90605156
Accidental exposure to product	40.12	16.13	46	18182	42320	90567899
COVID-19	39.93	16.13	98	18130	168745	90441474
Underdose	38.77	16.13	51	18177	53966	90556253
Systemic infection	38.68	16.13	19	18209	4756	90605463
Hyperglycaemia	37.95	16.13	49	18179	50921	90559298
Joint swelling	37.39	16.13	28	18200	503272	90106947
Injection site injury	37.28	16.13	12	18216	987	90609232
Weight decreased	36.35	16.13	162	18066	379748	90230471
Impaired healing	35.90	16.13	3	18225	234196	90376023
Lichen planus	34.85	16.13	15	18213	2776	90607443
Therapeutic product effect decreased	32.35	16.13	8	18220	277563	90332656
Illness	31.49	16.13	58	18170	81911	90528308
Thirst decreased	29.96	16.13	8	18220	341	90609878
Hyperglycaemic hyperosmolar nonketotic syndrome	29.84	16.13	11	18217	1358	90608861
Fungal infection	28.66	16.13	39	18189	42622	90567597
Lipase increased	28.29	16.13	21	18207	11090	90599129
Blood calcitonin increased	27.05	16.13	5	18223	36	90610183
Coronavirus test positive	26.39	16.13	9	18219	886	90609333
Musculoskeletal stiffness	25.41	16.13	14	18214	296518	90313701
Blister	24.99	16.13	10	18218	254988	90355231
Glomerular filtration rate decreased	24.35	16.13	23	18205	16909	90593310
Maternal exposure during pregnancy	24.28	16.13	22	18206	360041	90250178
Ketosis	23.33	16.13	8	18220	801	90609418
Toxicity to various agents	22.69	16.13	15	18213	287831	90322388
Intercepted product selection error	22.57	16.13	4	18224	22	90610197
Injury	22.39	16.13	6	18222	197343	90412876
Exposure during pregnancy	22.32	16.13	10	18218	238400	90371819
Pneumonia	22.09	16.13	61	18167	637998	89972221
Hepatic enzyme increased	22.07	16.13	24	18204	360712	90249507
Fibromyalgia	22.06	16.13	7	18221	206262	90403957
C-reactive protein increased	21.57	16.13	5	18223	181384	90428835
Injection site irritation	21.50	16.13	14	18214	6001	90604218
Rheumatoid arthritis	21.23	16.13	25	18203	362589	90247630
Glycosylated haemoglobin decreased	21.01	16.13	7	18221	642	90609577
Vision blurred	20.94	16.13	59	18169	110234	90499985
Product storage error	20.91	16.13	23	18205	20218	90590001
Vomiting projectile	20.24	16.13	9	18219	1800	90608419
Feeding disorder	20.03	16.13	21	18207	17491	90592728
Blindness transient	19.82	16.13	12	18216	4531	90605688
Diabetic retinopathy	19.67	16.13	10	18218	2692	90607527
Product prescribing error	19.40	16.13	27	18201	30118	90580101
Completed suicide	19.37	16.13	3	18225	145055	90465164
Nasopharyngitis	18.96	16.13	33	18195	407071	90203148
Increased appetite	18.89	16.13	17	18211	11748	90598471
Drug effect less than expected	18.84	16.13	13	18215	6125	90604094
Neutropenia	18.71	16.13	11	18217	224893	90385326
Off label use	18.47	16.13	138	18090	1102114	89508105
Device difficult to use	18.25	16.13	20	18208	17505	90592714
Dermatitis atopic	18.15	16.13	23	18205	23449	90586770
Hypertriglyceridaemia	18.07	16.13	14	18214	7875	90602344
Diabetic ketosis	17.96	16.13	6	18222	555	90609664
Joint range of motion decreased	17.68	16.13	3	18225	135640	90474579
Decreased activity	17.61	16.13	14	18214	8178	90602041
Intentional product use issue	17.50	16.13	11	18217	216881	90393338
Irritable bowel syndrome	17.47	16.13	10	18218	207438	90402781
Injection site nodule	17.44	16.13	11	18217	4462	90605757
Arthralgia	17.43	16.13	89	18139	778433	89831786
Product use issue	17.00	16.13	25	18203	329894	90280325
Injection site coldness	17.00	16.13	4	18224	101	90610118
Injection site discomfort	16.88	16.13	12	18216	5928	90604291
Idiopathic CD4 lymphocytopenia	16.70	16.13	3	18225	18	90610201
Injection site induration	16.56	16.13	15	18213	10453	90599766
Cholelithiasis	16.33	16.13	34	18194	52472	90557747
Bacterial translocation	16.21	16.13	6	18222	750	90609469

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood glucose increased	474.26	16.47	296	13587	73403	42534049
Accidental underdose	351.62	16.47	73	13810	598	42606854
Glycosylated haemoglobin increased	337.99	16.47	135	13748	12789	42594663
Injection site pain	326.38	16.47	214	13669	57584	42549868
Extra dose administered	250.28	16.47	87	13796	5582	42601870
Pancreatitis	246.02	16.47	161	13722	43107	42564345
Diabetic ketoacidosis	212.77	16.47	116	13767	22251	42585201
Nausea	207.32	16.47	420	13463	396379	42211073
Diabetes mellitus inadequate control	169.41	16.47	88	13795	15302	42592150
Inappropriate schedule of product administration	167.28	16.47	180	13703	95722	42511730
Pancreatitis acute	152.94	16.47	109	13774	33455	42573997
Incorrect dose administered	140.20	16.47	125	13758	52849	42554603
Diarrhoea	123.10	16.47	378	13505	460471	42146981
Injection site mass	117.81	16.47	57	13826	8518	42598934
Vomiting	112.52	16.47	273	13610	289450	42318002
Euglycaemic diabetic ketoacidosis	110.38	16.47	48	13835	5612	42601840
Injection site haemorrhage	98.25	16.47	56	13827	11680	42595772
Injection site erythema	97.55	16.47	68	13815	20127	42587325
Accidental overdose	89.44	16.47	74	13809	28256	42579196
Lactic acidosis	87.76	16.47	90	13793	45171	42562281
Hyperglycaemia	81.42	16.47	87	13796	45772	42561680
Metabolic acidosis	81.03	16.47	92	13791	51766	42555686
Injection site pruritus	79.05	16.47	45	13838	9360	42598092
Ketoacidosis	77.83	16.47	37	13846	5315	42602137
Glycosylated haemoglobin abnormal	75.53	16.47	18	13865	290	42607162
Blood glucose abnormal	68.17	16.47	37	13846	7016	42600436
Product dose omission issue	66.81	16.47	152	13731	154213	42453239
Pancreatic carcinoma	60.42	16.47	38	13845	9468	42597984
Weight decreased	56.42	16.47	172	13711	207776	42399676
Toxicity to various agents	56.30	16.47	5	13878	229131	42378321
Underdose	55.66	16.47	45	13838	16621	42590831
Obstructive pancreatitis	55.27	16.47	17	13866	738	42606714
Hyperlipasaemia	54.77	16.47	16	13867	581	42606871
Hypoglycaemia	52.57	16.47	80	13803	59774	42547678
Eructation	50.86	16.47	28	13855	5458	42601994
Lipase increased	49.66	16.47	35	13848	10531	42596921
Injection site swelling	48.74	16.47	42	13841	16931	42590521
Gastrointestinal disorder	40.45	16.47	62	13821	46591	42560861
Injection site bruising	40.36	16.47	32	13851	11493	42595959
Blood glucose decreased	38.44	16.47	34	13849	14185	42593267
Injury associated with device	37.89	16.47	15	13868	1382	42606070
Product storage error	37.02	16.47	30	13853	11110	42596342
Injection site rash	36.71	16.47	23	13860	5689	42601763
Injection site discomfort	36.51	16.47	17	13866	2329	42605123
Acute kidney injury	34.63	16.47	221	13662	367116	42240336
Pancreatic carcinoma metastatic	34.51	16.47	18	13865	3148	42604304
Febrile neutropenia	32.58	16.47	10	13873	185693	42421759
Dyspepsia	31.77	16.47	52	13831	41300	42566152
Injection site urticaria	30.63	16.47	17	13866	3366	42604086
Decreased appetite	28.91	16.47	132	13751	193005	42414447
Hyperkinetic heart syndrome	28.91	16.47	7	13876	121	42607331
Pyrexia	28.68	16.47	53	13830	393989	42213463
Disease progression	28.53	16.47	6	13877	143650	42463802
Abdominal discomfort	28.04	16.47	70	13813	75185	42532267
Pneumonia	27.97	16.47	60	13823	422089	42185363
Impaired gastric emptying	26.61	16.47	17	13866	4349	42603103
Injection site reaction	26.43	16.47	29	13854	15692	42591760
Off label use	25.13	16.47	115	13768	638220	41969232
Ketonuria	24.78	16.47	9	13874	655	42606797
Abdominal pain	24.75	16.47	125	13758	190346	42417106
Product administered at inappropriate site	23.84	16.47	14	13869	3084	42604368
Gastric dilatation	23.00	16.47	9	13874	804	42606648
Wrong drug	22.24	16.47	6	13877	162	42607290
Product monitoring error	21.59	16.47	15	13868	4408	42603044
Drug abuse	21.59	16.47	4	13879	104767	42502685
Completed suicide	21.40	16.47	3	13880	96462	42510990
Respiratory failure	20.56	16.47	8	13875	128124	42479328
Injection site nodule	19.95	16.47	11	13872	2150	42605302
Gangrene	19.61	16.47	15	13868	5111	42602341
Abdominal pain upper	19.29	16.47	65	13818	82544	42524908
Anaemia	19.22	16.47	39	13844	280239	42327213
Echocardiogram abnormal	19.14	16.47	9	13874	1261	42606191
Flatulence	18.46	16.47	31	13852	25121	42582331
Hyperamylasaemia	18.01	16.47	7	13876	614	42606838
Polyuria	17.76	16.47	19	13864	9992	42597460
Adenocarcinoma pancreas	17.75	16.47	9	13874	1485	42605967
White blood cell count decreased	17.53	16.47	7	13876	110389	42497063
Diabetic metabolic decompensation	17.50	16.47	10	13873	2092	42605360
Injection site injury	17.44	16.47	6	13877	372	42607080
Orchitis	16.87	16.47	10	13873	2241	42605211
Toe amputation	16.85	16.47	11	13872	2918	42604534
Spermatic cord inflammation	16.69	16.47	3	13880	10	42607442

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood glucose increased	545.27	15.14	342	22936	132154	110433867
Glycosylated haemoglobin increased	544.71	15.14	200	23078	23419	110542602
Diabetic ketoacidosis	392.96	15.14	187	23091	41871	110524150
Injection site pain	263.03	15.14	250	23028	177672	110388349
Euglycaemic diabetic ketoacidosis	262.60	15.14	97	23181	11526	110554495
Lactic acidosis	260.09	15.14	189	23089	92622	110473399
Pancreatitis	251.99	15.14	186	23092	93347	110472674
Pancreatitis acute	228.66	15.14	148	23130	60126	110505895
Nausea	204.11	15.14	645	22633	1235045	109330976
Acute kidney injury	194.97	15.14	419	22859	635011	109931010
Diabetes mellitus inadequate control	186.22	15.14	101	23177	29674	110536347
Vomiting	182.95	15.14	510	22768	910165	109655856
Extra dose administered	181.00	15.14	75	23203	12084	110553937
Accidental underdose	179.67	15.14	44	23234	1261	110564760
Hyperglycaemia	130.22	15.14	122	23156	84968	110481053
Hypoglycaemia	127.35	15.14	139	23139	115965	110450056
Diarrhoea	126.31	15.14	523	22755	1138982	109427039
Metabolic acidosis	121.02	15.14	126	23152	99618	110466403
Incorrect dose administered	118.77	15.14	127	23151	103514	110462507
Ketoacidosis	116.49	15.14	52	23226	10035	110555986
Product dose omission issue	112.18	15.14	224	23054	321558	110244463
Pancreatic carcinoma	111.60	15.14	57	23221	14815	110551206
Diabetic metabolic decompensation	101.06	15.14	36	23242	3853	110562168
Inappropriate schedule of product administration	84.80	15.14	153	23125	203484	110362537
Injury associated with device	82.38	15.14	32	23246	4357	110561664
Accidental overdose	80.58	15.14	75	23203	51759	110514262
Injection site pruritus	71.76	15.14	70	23208	51188	110514833
Blood glucose abnormal	70.30	15.14	40	23238	12876	110553145
Injection site erythema	69.15	15.14	92	23186	94084	110471937
Lipase increased	66.25	15.14	44	23234	18628	110547393
Injection site haemorrhage	65.76	15.14	55	23223	32973	110533048
Blood glucose decreased	60.57	15.14	50	23228	29438	110536583
Eructation	54.45	15.14	35	23243	14022	110551999
Obstructive pancreatitis	54.25	15.14	17	23261	1224	110564797
Weight decreased	52.38	15.14	216	23062	467841	110098180
Product administered at inappropriate site	50.38	15.14	24	23254	5369	110560652
Infusion related reaction	49.51	15.14	10	23268	381152	110184869
Wrong technique in product usage process	48.90	15.14	75	23203	87273	110478748
Toxicity to various agents	48.88	15.14	20	23258	480535	110085486
Hyperlipasaemia	47.24	15.14	16	23262	1473	110564548
Dehydration	46.61	15.14	147	23131	279364	110286657
Pancreatic carcinoma metastatic	46.59	15.14	21	23257	4143	110561878
Injection site mass	44.93	15.14	39	23239	24574	110541447
Systemic lupus erythematosus	41.95	15.14	3	23275	254335	110311686
Impaired gastric emptying	39.34	15.14	28	23250	13247	110552774
COVID-19	38.23	15.14	126	23152	244934	110321087
Transcription medication error	37.28	15.14	11	23267	646	110565375
Ketosis	37.27	15.14	14	23264	1740	110564281
Lower respiratory tract infection	37.02	15.14	4	23274	243102	110322919
Blood glucose fluctuation	37.01	15.14	22	23256	7676	110558345
Injection site rash	36.61	15.14	34	23244	23385	110542636
Glycosylated haemoglobin abnormal	35.97	15.14	10	23268	474	110565547
Stomatitis	35.27	15.14	7	23271	270235	110295786
Arthropathy	32.57	15.14	10	23268	287512	110278509
Ketonuria	32.49	15.14	12	23266	1423	110564598
Completed suicide	32.22	15.14	6	23272	242375	110323646
Product prescribing error	31.47	15.14	46	23232	51285	110514736
Lichen planus	31.32	15.14	15	23263	3395	110562626
Hyperkinetic heart syndrome	30.94	15.14	7	23271	141	110565880
Accidental exposure to product	30.93	15.14	45	23233	49963	110516058
Impaired healing	30.56	15.14	3	23275	196714	110369307
Injection site bruising	30.08	15.14	45	23233	51218	110514803
Joint swelling	29.29	15.14	30	23248	442815	110123206
Increased appetite	27.88	15.14	24	23254	14953	110551068
Drug abuse	26.80	15.14	3	23275	177408	110388613
Pneumonia	26.63	15.14	95	23183	876619	109689402
Decreased appetite	25.81	15.14	180	23098	475666	110090355
Diabetic ketosis	25.59	15.14	9	23269	927	110565094
Blood calcitonin increased	25.26	15.14	5	23273	51	110565970
Systemic infection	25.22	15.14	19	23259	9800	110556221
Injection site urticaria	25.01	15.14	24	23254	17191	110548830
Product monitoring error	24.56	15.14	18	23260	8909	110557112
Thirst decreased	24.55	15.14	7	23271	364	110565657
Contraindicated product administered	24.15	15.14	11	23267	248256	110317765
Adenocarcinoma pancreas	24.01	15.14	11	23267	2252	110563769
Disease progression	23.45	15.14	11	23267	244023	110321998
Wound	23.42	15.14	10	23268	234427	110331594
Device difficult to use	23.22	15.14	24	23254	18781	110547240
Wrong drug	23.20	15.14	7	23271	444	110565577
Cholelithiasis	23.05	15.14	45	23233	63377	110502644
Treatment failure	23.02	15.14	15	23263	277219	110288802
Off label use	22.92	15.14	204	23074	1499981	109066040
Orchitis	22.79	15.14	10	23268	1852	110564169
Coronavirus test positive	22.67	15.14	9	23269	1298	110564723
Injection site swelling	22.65	15.14	44	23234	61746	110504275
Febrile neutropenia	22.64	15.14	20	23258	316747	110249274
Neck dissection	22.40	15.14	3	23275	0	110566021
Maternal exposure during pregnancy	22.26	15.14	13	23265	254870	110311151
Therapeutic product effect decreased	22.00	15.14	12	23266	244304	110321717
Gastric dilatation	21.72	15.14	10	23268	2071	110563950
Injection site nodule	21.62	15.14	13	23265	4633	110561388
Fibromyalgia	21.13	15.14	5	23273	170904	110395117
Product administration interrupted	20.83	15.14	18	23260	11274	110554747
Musculoskeletal stiffness	20.81	15.14	17	23261	279805	110286216
Abdominal pain	20.59	15.14	181	23097	512808	110053213
Injection site injury	20.54	15.14	8	23270	1096	110564925
Pyrexia	20.18	15.14	109	23169	898156	109667865
Irritable bowel syndrome	19.92	15.14	5	23273	164210	110401811
Toe amputation	19.83	15.14	12	23266	4326	110561695
Dysuria	19.82	15.14	41	23237	60190	110505831
Hepatic enzyme increased	19.81	15.14	23	23255	320869	110245152
Underdose	19.45	15.14	42	23236	63512	110502509
Illness	19.34	15.14	49	23229	82122	110483899
Blister	19.29	15.14	12	23266	227364	110338657
Drug level increased	18.75	15.14	35	23243	47684	110518337
Product storage error	18.73	15.14	23	23255	21705	110544316
Glycosylated haemoglobin decreased	18.67	15.14	7	23271	865	110565156
Ill-defined disorder	18.60	15.14	5	23273	156848	110409173
Blood ketone body increased	18.55	15.14	7	23271	881	110565140
Urine ketone body present	18.51	15.14	11	23267	3835	110562186
Intentional product use issue	18.51	15.14	15	23263	247891	110318130
Drug effect less than expected	18.44	15.14	14	23264	7306	110558715
Spermatic cord inflammation	18.24	15.14	3	23275	9	110566012
Hyperglycaemic hyperosmolar nonketotic syndrome	18.23	15.14	10	23268	2999	110563022
Hepatic steatosis	18.18	15.14	35	23243	48796	110517225
Glucose urine present	17.83	15.14	9	23269	2280	110563741
Bursitis	17.73	15.14	3	23275	129915	110436106
Amylase increased	17.33	15.14	17	23261	12502	110553519
Decreased activity	17.28	15.14	16	23262	10958	110555063
Pancreatitis necrotising	17.22	15.14	12	23266	5489	110560532
Hypoglycaemic coma	17.16	15.14	12	23266	5521	110560500
Insulin resistance	17.07	15.14	8	23270	1726	110564295
Nasopharyngitis	16.98	15.14	36	23242	394325	110171696
Blood triglycerides increased	16.98	15.14	23	23255	23903	110542118
Injection site discomfort	16.94	15.14	13	23265	6894	110559127
Miosis	16.93	15.14	22	23256	21961	110544060
Therapy non-responder	16.88	15.14	6	23272	157301	110408720
Diabetic neuropathy	16.78	15.14	13	23265	6986	110559035
Flatulence	16.57	15.14	35	23243	52114	110513907
Idiopathic CD4 lymphocytopenia	16.57	15.14	3	23275	18	110566003
Pancytopenia	16.52	15.14	12	23266	209601	110356420
Echocardiogram abnormal	16.51	15.14	9	23269	2665	110563356
Hyperamylasaemia	16.39	15.14	7	23271	1214	110564807
Blindness transient	16.36	15.14	12	23266	5944	110560077
Lumbosacral radiculoplexus neuropathy	16.19	15.14	4	23274	119	110565902
Wheezing	16.07	15.14	18	23260	255212	110310809
Injection site irritation	16.02	15.14	11	23267	4913	110561108
Dermatitis atopic	15.81	15.14	23	23255	25518	110540503
Constipation	15.26	15.14	128	23150	357658	110208363

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10BJ05	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Glucagon-like peptide-1 (GLP-1) analogues
FDA CS	M0160181	Glucagon-Like Peptide 1
FDA MoA	N0000020058	Glucagon-like Peptide-1 (GLP-1) Agonists
MeSH PA	D000097789	Glucagon-Like Peptide-1 Receptor Agonists
MeSH PA	D007004	Hypoglycemic Agents
FDA EPC	N0000178480	GLP-1 Receptor Agonist

Related Drugs by ATC class:

A10BJ Glucagon-like peptide-1 (GLP-1) analogues 5 drugs

albiglutideexenatideliraglutidelixisenatidesemaglutide

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucagon-like peptide 1 receptor	GPCR	P43220	GLP1R_HUMAN	AGONIST				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
WTT295HSY5	UNII
D09889	KEGG_DRUG
4033739	VUID
N0000191089	NUI
4033739	VANDF
C3179549	UMLSCUI
CHEMBL2108027	ChEMBL_ID
DB09045	DRUGBANK_ID
9164	INN_ID
C555680	MESH_SUPPLEMENTAL_RECORD_UI
7638	IUPHAR_LIGAND_ID
1551291	RXNORM
228834	MMSL
30573	MMSL
d08290	MMSL
015693	NDDF
714080005	SNOMEDCT_US
714081009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Trulicity	HUMAN PRESCRIPTION DRUG LABEL	1	0002-1433	INJECTION, SOLUTION	0.75 mg	SUBCUTANEOUS	BLA	36 sections
Trulicity	HUMAN PRESCRIPTION DRUG LABEL	1	0002-1434	INJECTION, SOLUTION	1.50 mg	SUBCUTANEOUS	BLA	36 sections
Trulicity	HUMAN PRESCRIPTION DRUG LABEL	1	0002-2236	INJECTION, SOLUTION	3 mg	SUBCUTANEOUS	BLA	36 sections
Trulicity	HUMAN PRESCRIPTION DRUG LABEL	1	0002-3182	INJECTION, SOLUTION	4.50 mg	SUBCUTANEOUS	BLA	36 sections
Trulicity	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3483	INJECTION, SOLUTION	1.50 mg	SUBCUTANEOUS	BLA	34 sections
Trulicity	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3484	INJECTION, SOLUTION	0.75 mg	SUBCUTANEOUS	BLA	34 sections
Trulicity	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5467	INJECTION, SOLUTION	3 mg	SUBCUTANEOUS	BLA	34 sections
TRULICITY	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6453	INJECTION, SOLUTION	0.75 mg	SUBCUTANEOUS	BLA	34 sections
TRULICITY	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6456	INJECTION, SOLUTION	1.50 mg	SUBCUTANEOUS	BLA	34 sections
TRULICITY	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6571	INJECTION, SOLUTION	3 mg	SUBCUTANEOUS	BLA	34 sections
TRULICITY	HUMAN PRESCRIPTION DRUG LABEL	1	50090-7589	INJECTION, SOLUTION	4.50 mg	SUBCUTANEOUS	BLA	35 sections